Sirtex Medical announced the publication of a six-year retrospective analysis of 325 patients treated with its targeted radioactive SIR-Spheres microspheres therapy for inoperable primary liver cancer.
The study is the largest multicenter evaluation of radioembolisation (also known as Selective Internal Radiation Therapy or SIRT) using SIR-Spheres microspheres for patients with inoperable primary liver cancer. The results confirm that the treatment was safe and effective in a range of patients with early to advanced stages of the disease.
“These positive results build on the growing body of robust clinical evidence that demonstrates SIR-Spheres microspheres deliver very encouraging clinical outcomes across the different stages of liver cancer,” Sirtex chief executive officer, Gilman Wong, says.
The study results are published in the American Association of the Study of Liver Diseases, Hepatology.
Release Date: July 7, 2011
Filed Under: Drug Discovery